Concepts (64)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2025 | 43 | 0.610 |
Why?
|
| Mycoses | 2 | 2016 | 9 | 0.540 |
Why?
|
| Neutropenia | 2 | 2017 | 41 | 0.530 |
Why?
|
| Hospital Design and Construction | 1 | 2013 | 1 | 0.410 |
Why?
|
| Environmental Exposure | 1 | 2013 | 51 | 0.390 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2013 | 44 | 0.390 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 433 | 0.330 |
Why?
|
| Infant | 4 | 2025 | 1025 | 0.180 |
Why?
|
| Hypercalcemia | 1 | 2021 | 13 | 0.170 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2021 | 9 | 0.170 |
Why?
|
| Carcinoma, Small Cell | 1 | 2021 | 15 | 0.170 |
Why?
|
| Prognosis | 3 | 2025 | 811 | 0.150 |
Why?
|
| Child, Preschool | 3 | 2025 | 1173 | 0.150 |
Why?
|
| Child | 4 | 2025 | 2287 | 0.140 |
Why?
|
| Primary Myelofibrosis | 1 | 2017 | 9 | 0.130 |
Why?
|
| Osteosarcoma | 1 | 2017 | 17 | 0.130 |
Why?
|
| Vesicular Transport Proteins | 1 | 2017 | 34 | 0.130 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 31 | 0.130 |
Why?
|
| Febrile Neutropenia | 1 | 2016 | 2 | 0.130 |
Why?
|
| Methotrexate | 2 | 2017 | 36 | 0.130 |
Why?
|
| Bone Marrow | 1 | 2017 | 83 | 0.130 |
Why?
|
| Hematologic Neoplasms | 1 | 2016 | 23 | 0.120 |
Why?
|
| Ovarian Neoplasms | 1 | 2021 | 607 | 0.110 |
Why?
|
| Antifungal Agents | 1 | 2013 | 69 | 0.100 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2012 | 6 | 0.090 |
Why?
|
| Survival Rate | 1 | 2013 | 432 | 0.090 |
Why?
|
| Central Nervous System Diseases | 1 | 2012 | 13 | 0.090 |
Why?
|
| Female | 6 | 2025 | 15624 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 42 | 0.090 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 480 | 0.090 |
Why?
|
| Dexamethasone | 1 | 2012 | 63 | 0.090 |
Why?
|
| Immunologic Factors | 1 | 2012 | 50 | 0.090 |
Why?
|
| Kidney Transplantation | 1 | 2012 | 44 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 209 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 1032 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2016 | 2635 | 0.080 |
Why?
|
| Humans | 7 | 2025 | 28851 | 0.070 |
Why?
|
| Male | 4 | 2025 | 13921 | 0.070 |
Why?
|
| Adolescent | 3 | 2025 | 3193 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2017 | 67 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2025 | 288 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2021 | 54 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 841 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2021 | 249 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 415 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2021 | 523 | 0.030 |
Why?
|
| Homozygote | 1 | 2017 | 36 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2017 | 77 | 0.030 |
Why?
|
| Reference Standards | 1 | 2016 | 57 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 46 | 0.030 |
Why?
|
| Cisplatin | 1 | 2017 | 186 | 0.030 |
Why?
|
| Mass Screening | 1 | 2016 | 158 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 481 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2017 | 916 | 0.030 |
Why?
|
| Mutation | 1 | 2017 | 867 | 0.020 |
Why?
|
| Infusions, Intraventricular | 1 | 2012 | 1 | 0.020 |
Why?
|
| Seizures | 1 | 2012 | 49 | 0.020 |
Why?
|
| Rituximab | 1 | 2012 | 64 | 0.020 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2012 | 28 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2012 | 43 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2012 | 285 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2012 | 634 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2012 | 2426 | 0.010 |
Why?
|
| Adult | 1 | 2012 | 8024 | 0.010 |
Why?
|